Anna Cardellino
Research Subjects
Research Interests
Anna Cardellino has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Barbara J. Kuter
Merck Sharp & Dohme Corp.; Whitehouse Station, NJ USA
1 shared publication- Brenda Colatrella
Product Donations, Merck & Co., Inc., Whitehouse Station, NJ 08889, USA
1 shared publication - Diana Klotz
Merck Sharp & Dohme Corp.; Whitehouse Station, NJ USA
1 shared publication - Mark B. Feinberg
Merck Vaccines, Merck & Company, Inc., West Point, PA 19486
1 shared publication - Shazia S. Khawaja
Merck Sharp & Dohme Corp., Whitehouse Station, NJ
1 shared publication - T. Christopher Mast
Merck Sharp & Dohme Corp.; Whitehouse Station, NJ USA
1 shared publication
Latest Publications
- 12 June 2012
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (6) , 777-782
Evaluating the health impact of a public-private partnership
The purpose of this article is to describe the RotaTeq(®) Nicaragua Partnership and the evaluation of the public health impact of the vaccine conducted by the partners, including the creation of a rotavirus surveillance program and a vaccine effectiveness assessment. The three main objectives of the partnership were to demonstrate that a new rotavirus vaccine could (1) be introduced rapidly in a developing country, (2) be successfully integrated into the existing vaccine delivery infrastructure, and (3) have a significant and measurable public health impact at the end of the 3-y program. The vaccine impact assessment required collaboration among partners with different areas of expertise, including the Nicaraguan Ministry of Health, Merck, local hospitals, government health clinics, laboratories, and a Technical Advisory Group. Through the partnership, RotaTeq(®) became available in a GAVI-eligible developing country, Nicaragua, in the same year it was approved in the United States. Vaccine coverage rapidly reached over > 90% of eligible Nicaraguan children. The impact assessment evaluated over 10,000 subjects and leveraged and enhanced the existing diarrheal surveillance infrastructure, ultimately providing the scientific community with some of the first real-world rotavirus vaccine effectiveness data from a developing country. The successful public-private partnership (PPP) was internationally recognized as a model for the rapid adoption of a new vaccine in a developing world setting. The model could be adapted to benefit other PPPs interested in demonstrating the impact of their own programs.
- 12 June 2012
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (6) , 777-782
Evaluating the health impact of a public-private partnership
The purpose of this article is to describe the RotaTeq(®) Nicaragua Partnership and the evaluation of the public health impact of the vaccine conducted by the partners, including the creation of a rotavirus surveillance program and a vaccine effectiveness assessment. The three main objectives of the partnership were to demonstrate that a new rotavirus vaccine could (1) be introduced rapidly in a developing country, (2) be successfully integrated into the existing vaccine delivery infrastructure, and (3) have a significant and measurable public health impact at the end of the 3-y program. The vaccine impact assessment required collaboration among partners with different areas of expertise, including the Nicaraguan Ministry of Health, Merck, local hospitals, government health clinics, laboratories, and a Technical Advisory Group. Through the partnership, RotaTeq(®) became available in a GAVI-eligible developing country, Nicaragua, in the same year it was approved in the United States. Vaccine coverage rapidly reached over > 90% of eligible Nicaraguan children. The impact assessment evaluated over 10,000 subjects and leveraged and enhanced the existing diarrheal surveillance infrastructure, ultimately providing the scientific community with some of the first real-world rotavirus vaccine effectiveness data from a developing country. The successful public-private partnership (PPP) was internationally recognized as a model for the rapid adoption of a new vaccine in a developing world setting. The model could be adapted to benefit other PPPs interested in demonstrating the impact of their own programs.